LV11823B - Preparāts olnīcu estrogēnu toniskās sekrēcijas atjaunošanai ilgstošas ārstēšanas režīmā - Google Patents
Preparāts olnīcu estrogēnu toniskās sekrēcijas atjaunošanai ilgstošas ārstēšanas režīmā Download PDFInfo
- Publication number
- LV11823B LV11823B LVP-97-30A LV970030A LV11823B LV 11823 B LV11823 B LV 11823B LV 970030 A LV970030 A LV 970030A LV 11823 B LV11823 B LV 11823B
- Authority
- LV
- Latvia
- Prior art keywords
- preparation
- estrogen
- gnrh antagonist
- gnrh
- proliferation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (15)
- LV 11823 IZGUDROJUMA FORMULA 1. Preparāts no dzimumdziedzem steroīdo hormonu (GnRH) atkarīgo stāvokļu terapeitiskai ārstēšanai zīdītājiem, kas samazina estrogēnu izdalīšanos un kas satur GnRH antagonistu daudzumā, kas efektīvi pārtrauc endometrija audu proliferāciju bez būtiskas endogēno estrogēnu producēšanas pārtraukšanas.
- 2. Preparāts saskaņā ar 1. punktu atšķiras ar to, ka zīdītājs ir menstruējošā sieviete.
- 3. Preparāts saskaņā ar 1. punktu atšķiras ar to, ka GnRH antagonists ir izmantots daudzumā, kas ir efektīvs endometrija audu proliferācijas pārtraukšanai, bet nepietiekams, lai uzkrājoties izraisītu kastrātiem līdzīgo endogēno estrogēnu līmeni.
- 4. Preparāts saskaņā ar 3. punktu atšķiras ar to, ka daudzums, kas ir efektīvs, lai bremzētu endometrija audu proliferāciju, arī ir efektīvs, lai aizkavētu asiņošanas (menstruācijas) iztrūkumu.
- 5. Preparāts endometrija audu proliferācijas samazināšanai menstruējošai sievietei, kas neizraisa kastrātiem līdzīgo endogēno estrogēnu līmeni, atšķiras ar to, ka satin GnRH antagonistu daudzumā, lai efektīvi bremzētu endometrija audu proliferāciju menstruējošai sievietei, bet nav tādā daudzumā, lai būtiski pārtrauktu endogēno estrogēnu producēšanu.
- 6. Preparāts saskaņā ar 5. punktu atšķiras ar to, ka GnRH antagonists ir izmantots tādā daudzumā, kurš ir efektīvs, lai nodrošinātu 24 stundās vidējo seruma estradiola koncentrāciju aptuveni no 30 līdz 50 pg/ml.
- 7. Preparāts saskaņā ar 6. punktu atšķiras ar to, ka GnRH antagonists ir izmantots tādā daudzumā, kurš ir efektīvs, lai nodrošinātu 24 stundās vidējo seruma estradiola koncentrāciju aptuveni no 30 līdz 45 pg/ml.
- 8. Preparāts endometrija audu proliferācijas samazināšanai menstruējošai sievietei, kas neizraisa endogēno estrogēnu kastrātu līmeni, atšķiras ar to, ka satur GnRH antagonistu efektīvā daudzumā, lai bremzētu endometrija audu proliferāciju menstruējošai sievietei, bet nav efektīvs, lai būtiski pārtrauktu endogēno estrogēnu producēšanu.
- 9. Preparāts saskaņā ar 8. punktu atšķiras ar to, ka GnRH antagonists ir izmantots tādā daudzumā, kurš ir efektīvs lai nodrošinātu 24 stundās vidējo seruma estradiola koncentrāciju aptuveni no 30 līdz 50 pg/ml.
- 10. Preparāts saskaņā ar 9. punktu atšķiras ar to, ka seruma estradiola līmenis ir aptuveni no 35 līdz 45 pg/ml.
- 11. Preparāts no dzimumdziedzeru steroīdo hormonu (GnRH) atkarīgo stāvokļu atvieglošanai menstruējošai sievietei, kas neizraisa kastrācijai raksturīgo endogēno estrogēnu līmeni, atšķiras ar to, ka satur GnRH antagonistu efektīvā daudzumā, lai bremzētu endometrija audu proliferāciju menstruējošai sievietei, bet kas nav efektīvs, lai būtiski pārtrauktu endogēno estrogēnu producēšanu.
- 12. Preparāts saskaņā ar 11. punktu atšķiras ar to, ka GnRH antagonists ir izmantots tādā daudzumā, kurš ir efektīvs, lai nodrošinātu 24 stundās vidējo seruma estradiola koncentrāciju aptuveni no 30 līdz 50 pg/ml.
- 13. Preparāts saskaņā ar 12. punktu atšķiras ar to, ka seruma estradiola līmenis ir aptuveni no 35 līdz 45 pg/ml.
- 14. Preparāts saskaņā ar 11. punktu atšķiras ar to, ka no gonādu steroīdiem atkarīgais stāvoklis ir endometrioze.
- 15. Preparāts saskaņā ar 11. punktu atšķiras ar to, ka no gonādu steroīdiem atkarīgais stāvoklis ir leiomioma.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27959394A | 1994-07-22 | 1994-07-22 | |
| US08/467,860 US5658884A (en) | 1994-07-22 | 1995-06-06 | Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens |
| PCT/US1995/008996 WO1996003138A1 (en) | 1994-07-22 | 1995-07-18 | Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV11823A LV11823A (lv) | 1997-08-20 |
| LV11823B true LV11823B (lv) | 1998-03-20 |
Family
ID=26959766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-97-30A LV11823B (lv) | 1994-07-22 | 1997-02-26 | Preparāts olnīcu estrogēnu toniskās sekrēcijas atjaunošanai ilgstošas ārstēšanas režīmā |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0769956B1 (lv) |
| JP (1) | JP3138477B2 (lv) |
| CN (1) | CN1137722C (lv) |
| AP (1) | AP775A (lv) |
| AT (1) | ATE190494T1 (lv) |
| AU (1) | AU691952B2 (lv) |
| BG (1) | BG63363B1 (lv) |
| BR (1) | BR9508718A (lv) |
| CA (1) | CA2195745C (lv) |
| CY (1) | CY2228B1 (lv) |
| CZ (1) | CZ291803B6 (lv) |
| DE (1) | DE69515666T2 (lv) |
| DK (1) | DK0769956T3 (lv) |
| EE (1) | EE03515B1 (lv) |
| ES (1) | ES2145286T3 (lv) |
| FI (1) | FI970244A0 (lv) |
| GR (1) | GR3033590T3 (lv) |
| HU (1) | HU218910B (lv) |
| IL (1) | IL114655A (lv) |
| IS (1) | IS4413A (lv) |
| LV (1) | LV11823B (lv) |
| MX (1) | MX9700574A (lv) |
| NO (1) | NO970257L (lv) |
| NZ (1) | NZ290554A (lv) |
| OA (1) | OA10730A (lv) |
| PT (1) | PT769956E (lv) |
| RU (1) | RU2181598C2 (lv) |
| SK (1) | SK282118B6 (lv) |
| WO (1) | WO1996003138A1 (lv) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8173592B1 (en) | 1999-03-31 | 2012-05-08 | Zentaris Ivf Gmbh | Method for a programmed controlled ovarian stimulation protocol |
| EP1214086A2 (en) * | 1999-09-23 | 2002-06-19 | Zentaris AG | Method for the therapeutic management of endometriosis and fallopian tube obstruction |
| DE10137174A1 (de) * | 2001-07-31 | 2003-02-13 | Zentaris Ag | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
| GB0616111D0 (en) * | 2006-06-16 | 2006-09-20 | Ardana Bioscience Ltd | Agents, methods and uses |
| EP2095818A1 (en) * | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Use of LHRH antagonists at non-castrating doses |
| WO2009145690A1 (en) * | 2008-05-29 | 2009-12-03 | Isr Immune System Regulation Ab | Method and means for treating viral disease, in particular hiv/aids |
| EP3560555A1 (en) * | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171835A (en) * | 1988-10-21 | 1992-12-15 | The Administrators Of The Tulane Educational Fund | LHRH antagonists |
| US5169932A (en) * | 1989-10-30 | 1992-12-08 | The Salk Institute For Biological Studies | Gnrh analogs |
| US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
| ZA924811B (en) * | 1991-06-28 | 1993-12-29 | Endorecherche Inc | Controlled release systems and low dose androgens |
| US5681817A (en) * | 1994-02-04 | 1997-10-28 | The Medical College Of Hampton Roads | Treatment of ovarian estrogen dependent conditions |
| US5407955A (en) * | 1994-02-18 | 1995-04-18 | Eli Lilly And Company | Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease |
-
1995
- 1995-07-18 AP APAP/P/1997/000913A patent/AP775A/en active
- 1995-07-18 PT PT95927228T patent/PT769956E/pt unknown
- 1995-07-18 EP EP95927228A patent/EP0769956B1/en not_active Revoked
- 1995-07-18 EE EE9700208A patent/EE03515B1/xx not_active IP Right Cessation
- 1995-07-18 WO PCT/US1995/008996 patent/WO1996003138A1/en not_active Application Discontinuation
- 1995-07-18 AT AT95927228T patent/ATE190494T1/de not_active IP Right Cessation
- 1995-07-18 JP JP08505816A patent/JP3138477B2/ja not_active Expired - Lifetime
- 1995-07-18 IL IL11465595A patent/IL114655A/xx not_active IP Right Cessation
- 1995-07-18 HU HU9700046A patent/HU218910B/hu not_active IP Right Cessation
- 1995-07-18 ES ES95927228T patent/ES2145286T3/es not_active Expired - Lifetime
- 1995-07-18 NZ NZ290554A patent/NZ290554A/xx not_active IP Right Cessation
- 1995-07-18 DE DE69515666T patent/DE69515666T2/de not_active Revoked
- 1995-07-18 SK SK70-97A patent/SK282118B6/sk not_active IP Right Cessation
- 1995-07-18 MX MX9700574A patent/MX9700574A/es unknown
- 1995-07-18 BR BR9508718A patent/BR9508718A/pt not_active Application Discontinuation
- 1995-07-18 AU AU31320/95A patent/AU691952B2/en not_active Expired
- 1995-07-18 CZ CZ1997150A patent/CZ291803B6/cs not_active IP Right Cessation
- 1995-07-18 DK DK95927228T patent/DK0769956T3/da active
- 1995-07-18 CA CA002195745A patent/CA2195745C/en not_active Expired - Lifetime
- 1995-07-18 CN CNB951951696A patent/CN1137722C/zh not_active Expired - Fee Related
- 1995-07-18 RU RU97102759/14A patent/RU2181598C2/ru not_active IP Right Cessation
-
1997
- 1997-01-13 OA OA60952A patent/OA10730A/en unknown
- 1997-01-14 IS IS4413A patent/IS4413A/is unknown
- 1997-01-21 FI FI970244A patent/FI970244A0/fi not_active Application Discontinuation
- 1997-01-21 NO NO970257A patent/NO970257L/no not_active Application Discontinuation
- 1997-01-21 BG BG101158A patent/BG63363B1/bg unknown
- 1997-02-26 LV LVP-97-30A patent/LV11823B/lv unknown
-
2000
- 2000-05-31 GR GR20000401285T patent/GR3033590T3/el not_active IP Right Cessation
-
2001
- 2001-07-26 CY CY0100017A patent/CY2228B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0785792B1 (en) | Treatment of ovarian estrogen dependent conditions | |
| EP0686037B1 (en) | Hormone replacement therapy | |
| Maheux et al. | Use of intranasal luteinizing hormone-releasing hormone agonist in uterine leiomyomas | |
| US5552394A (en) | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy | |
| WO2006042021A2 (en) | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | |
| Bygdeman et al. | Contraceptive use of antiprogestin | |
| CA2195745C (en) | Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens | |
| Hodgen | Pregnancy prevention by intravaginal delivery of a progesterone antagonist: RU486 tampon for menstrual induction and absorption | |
| Reichel et al. | Goserelin (Zoladex) depot in the treatment of endometriosis | |
| US5658884A (en) | Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens | |
| Mettler et al. | Experience with a depot GnRH-agonist (Zoladex) in the treatment of genital endometriosiss | |
| Pasquale | Rationale for a triphasic oral contraceptive | |
| US5116818A (en) | Method and kit for contraception with GnRH-antagonist | |
| Lipitz et al. | Suppression with gonadotropin-releasing hormone analogues prior to stimulation with gonadotropins: comparison of three protocols | |
| DANAZOL et al. | A. LEMAY and HRPI buserelin protocol 310 study group Endocrinology of Reproduction, Hospital Saint-Francoise D'Assise, Quebec G1L 3L5, Canada; Hoechst-Roussel Pharmaceuticals Inc. Somerville, New Jersey, USA | |
| Reid et al. | LHRH agonists and antagonists: therapeutic possibilities for premenstrual syndrome |